Trial · NCT06955169
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
NCT06955169, Phase 2, Recruiting, RTOG Foundation, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment. Trials, record NCT06955169. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06955169
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
- NCT number
- NCT06955169
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 130 participants, estimated
- Lead sponsor
- RTOG Foundation, Inc.
- Conditions
- Intracranial Meningioma
- Interventions
- [177Lu]Lu-DOTATATE, Standard of Care treatments
- First posted
- 2025-05-02
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Assessed up to 4 years | Proportion of patients alive without disease progression per current RANO meningioma criteria |
| Secondary | Progression free survival at 6 months (PFS-6) | 6 months | Proportion of participants alive without progression at 6 months assessed per RANO meningioma criteria |
| Secondary | Overall Survival at 12 months (OS-12) | 12 months | Proportion of participants alive at 12 months |
| Secondary | Overall survival (OS) | Assessed up to 4 years | Proportion of patients after cross-over alive without disease progression per current RANO meningioma criteria |
| Secondary | Progression-free Survival after cross-over (PFS2) | Assessed up to 4 years | Time from cross-over to disease progression per RANO meningioma criteria or death from any cause, whichever occurs first. |
| Secondary | Disease Control Rate (DCR) | Assessed up to 4 years | Proportion of patients achieving complete response, partial response, minor response or stable disease as per RANO meningioma criteria |
| Secondary | Objective response rate (ORR) | Assessed up to 4 years | Proportion of patients achieving complete or partial response as per RANO meningioma criteria. |
| Secondary | Number of participants by highest grade treatment-emergent adverse event (TEAE): | Assessed up to 4 years | Number of participants experiencing the highest grade TEAE, graded according to CTCAE version 5.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to adverse event). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06955169
GET https://conductscience.org/api/trials/v1/NCT06955169/registered